Table 3 Affected cancer-related canonical pathways in GOT1 tumors after sonidegib, ¹⁷⁷Lu-octreotate, or combination of both treatments

Wnt/β-catenin

Sonidegib

-

-

signaling

¹⁷⁷Lu-octreotate

0.045

DOWN: SOX2, TLE4, WNT11

Combination

0.003

UP: CDKN2A, PPP2R2C

DOWN: FZD9, GNAQ, ILK, SOX2, TCF4, TGFB3, TLE4, WNT11

PI3K/AKT/mTOR signaling

Sonidegib

-

-

¹⁷⁷Lu-octreotate

0.110

UP: CDKN1B

DOWN: NFKBIA

Combination

0.013

UP: CDKN1A, CDKN1B, PPP2R2C, PTEN

DOWN: ILK, ITGA3, NFKBIA

G-protein coupled

Sonidegib

-

-

receptor signaling

¹⁷⁷Lu-octreotate

-

-

Combination

0.043

UP: GNAQ, GNAS, GRM8, PDE5A, RGS10, RGS16

DOWN: ADCY3, CAMK2B, GNAI2, NFKBIA

Notch signaling

Sonidegib

-

-

¹⁷⁷Lu-octreotate

-

-

Combination

0.043

DOWN: DLL1, LFNG, PSENEN

NF-ΚB signaling

Sonidegib

0.048

UP: PDGFRA

¹⁷⁷Lu-octreotate

0.181

DOWN: GHR, NFKBIA

Combination

-

-